ABZORB is the trusted choice of doctors for over two decades and the No. 1 choice of skin specialists*.
Mumbai, April 30, 2018: Sun Pharma Consumer Healthcare (CHC), a division of Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) announced its entry into the anti-fungal powder OTC category with ABZORB. The brand will be co-promoted across prescription & OTC channels in India to drive growth. Sun Pharma CHC has launched a 360° marketing campaign comprising TV, print & digital to expand consumer outreach.
Commenting on the development, Vidhi Salgaocar, Head, Consumer Healthcare, Sun Pharma said, “We are excited to offer consumers the Brand of Choice by dermatologists – ABZORB. Fungal infections are a common occurrence and are often left untreated because of the associated social stigma. The intent of the 3600 marketing campaign is to raise consumer awareness regarding fungal infections and empower them to treat the infection and lead a healthier life. ”
The new campaign by Lowe Lintas, Mumbai uses an interesting character to convey the brand message, “You are not yourself when itch strikes you” or “Jab khujli sataye aap aap na reh payien.” Consumer research has shown that most people are uncomfortable discussing fungal infections (especially itching) with anyone (not even with their doctors sometimes). They will suffer incessant itching, irritation, pain and burning silently. Itch attacks cause a lot of embarrassment especially in the middle of a meeting or any other occasions. The sensation to itch is severe and impossible to control. The new TVC conveys the message in an interesting & engaging way and explains the product’s functionality.
The anti-fungal powder category is estimated to be over Rs. 100 crore in India (IMS MAT August 2017) and ABZORB is a key player in the segment. Inconsistent weather conditions with increasing instances of high temperatures and unexpected rain has increased the incidence of fungal infections, with the category growing at over 15% every year.
* SMSRC MAT August 2017